Point of Care Nano-Technology, Inc.: M&A transaction — PCNT acquires EZ Saliva diagnostic assets, issues 66M shares; control shifts to Dr. Guirguis

Point of Care Nano-Technology, Inc.

Acquired substantially all assets of Point of Care Nano-Technology, LLC, including EZ Saliva test kit IP and $101,400 cash, for 66M restricted shares.
Dr. Raouf Guirguis became director and Chief Scientific Officer; his group obtained ~48.4% of outstanding common stock.
Nathan Keele joined board with ~26.5% stake; previous controller Nicholas DeVito surrendered super-majority preferred for 5M common shares, remains CEO.
Entered exclusive perpetual license with Zeus Diagnostics for oral-fluid patents in N.America; $35K upfront plus 7.5% royalty.
Company to focus on commercializing EZ Saliva products; financial statements of acquired business to be filed by amendment.

item 1.01 item 2.01 item 5.01 item 1.1 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

Point of Care Nano-Technology, Inc. completed an acquisition involving Point of Care Nano-Technology, LLC for 66,000,000 restricted shares of the Company’s common stock (closed 2024-05-20).

Action: acquisition
Counterparty: Point of Care Nano-Technology, LLC
Consideration: 66,000,000 restricted shares of the Company’s common stock
Closing: 2024-05-20

Exact text from the filing

of human saliva, referred to as the “EZ Saliva” test kits, and cash in the amount of $101,400. In exchange for the Assets, the Company is issuing to Point and/or its designees 66,000,000 restricted shares of the Company’s common stock (the “Consideration Shares”). Upon the closing of the Acquisition, which effected a change of control of the Company, Dr. Raouf

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

Point of Care Nano-Technology, Inc. underwent a change of control involving Point of Care Nano-Technology, LLC for 66,000,000 restricted shares of the Company’s common stock (closed 2024-05-20).

Action: change of control
Counterparty: Point of Care Nano-Technology, LLC
Consideration: 66,000,000 restricted shares of the Company’s common stock
Closing: 2024-05-20

Exact text from the filing

of human saliva, referred to as the “EZ Saliva” test kits, and cash in the amount of $101,400. In exchange for the Assets, the Company is issuing to Point and/or its designees 66,000,000 restricted shares of the Company’s common stock (the “Consideration Shares”). Upon the closing of the Acquisition, which effected a change of control of the Company, Dr. Raouf

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001199835-24-000220

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.